Allogeneic Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant of Hematological Malignancies

2008 ASBMT Online Seminar
Claudio Anasetti, MD and Benjamin Djulbegovic, MD
Moffitt Cancer Center
University of South Florida

Objectives: This presentation from the Moffitt Cancer Center, University of South Florida, compares stem cell sources from bone marrow versus peripheral blood. Dr. Anasetti reviews well-recognized data that show higher doses of CD34 cells protect against mortality. This information led Dr. Djulbegovic and collaborators to evaluate several published studies (total patients=1100) and report a meta-analysis to determine which product is better for a particular disease and for what reasons. He presents considerable significant detail. The conclusion is peripheral blood and bone marrow produce different products; the choice for a patient should be individualized, based on the ultimate goals of survival and quality of life.